title: Development and comparative evaluation of in vitro, in vivo properties of novel controlled release compositions of paroxetine hydrochloride hemihydrate as against Geomatrix™ platform technology.
abstract: The objective of this study is to develop, in vitro and in vivo evaluation of novel approaches for controlled release of paroxetine hydrochloride hemihydrate (PHH) in comparison to patented formulation PAXIL CR(®) tablets of GlaxoSmithKline (Geomatrix™ technology). In one of the approaches, hydrophilic core matrix tablets containing 85% of the dose were prepared and further coated with methacrylic acid copolymer to delay the release. An immediate release coating of 15% was given as top coat. The tablets were further optionally coated using ethyl cellulose. In the second approach, hydrophobic matrix core tablets containing metharylic acid copolymer were prepared. In the third approach, PHH was granulated with enteric polymer and further hydrophobic matrix core tablets were prepared. The effect of polymer concentration, level of enteric coating on drug release was evaluated by in vitro dissolution study by varying dissolution apparatus and the rotation speeds. It was found that increase in concentration of high viscosity hydroxypropylmethylcellulose (HPMC) resulted in reduction of the release rate. The drug release was observed to be dependent on the level of enteric coating and ethyl cellulose coating, being slower at increased coating. The release mechanism of PHH followed zero-order shifting to dissolution dependent by the increase of HPMC content. The formulation was stable without change in drug release rate. In vivo study in human volunteers confirmed the similarity between test and innovator formulations. In conclusion, HPMC-based matrix tablets, which were further coated using methacrylic acid copolymer, were found to be suitable for the formulation of single layer-controlled release PHH.
authors.affiliation: Formulation Research Division, Aurobindo Pharma Limited Research Centre, Quthubullapur, Hyderabad, India. khatavkarun@indiatimes.com
authors.forename: Umesh Nandkumar
authors.initials: UN
authors.lastname: Khatavkar
authors.forename: Shamkant Laxman
authors.initials: SL
authors.lastname: Shimpi
authors.forename: K
authors.initials: K
authors.lastname: Jayaram Kumar
authors.forename: Kishor Dattatraya
authors.initials: KD
authors.lastname: Deo
mesh_terms: D000293:Adolescent; D000328:Adult; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D006801:Humans; D065347:Hypromellose Derivatives; D008297:Male; D008747:Methylcellulose / Q000008:administration & dosage / Q000031:analogs & derivatives; D008875:Middle Aged; D017374:Paroxetine / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage*; D012995:Solubility; D013607:Tablets; D013608:Tablets, Enteric-Coated
chemical_list: D003692:Delayed-Action Preparations; D065347:Hypromellose Derivatives; D008747:Methylcellulose; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors; D013607:Tablets; D013608:Tablets, Enteric-Coated